PRDX2 and glioblastoma: To prove that this compound decreases GBM cell viability through the inhibition of PRDX2, it would be necessary to compare the influence of CONA on the phenotype of the wild type and either the PRDX2-silenced cells or the cells containing mutated PRDX2 that are unable to bind CONA.